Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Renal >90% (as amino acids and metabolites); fecal <5%
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution